Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal

Journal of Urology

Volumn 157, Issue 4, 1997, Pages 1204-1207

  Small, Eric J ^a,b   Baron, Ari D ^b   Fippin, Linda ^b   Apodaca, Dan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

flutamide; ketoconazole; neoplasm metastasis; prostate specific antigen; prostatic neoplasms

Indexed keywords

BICALUTAMIDE; CORTICOSTEROID; FLUTAMIDE; HYDROCORTISONE; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FATIGUE; HUMAN; LIVER TOXICITY; MALE; METASTASIS; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; RASH; TREATMENT OUTCOME;

EID: 0030999075     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64924-3     Document Type: Article

References (20)

1. Smith D. C., Bahnson, R. R. and Trump, D. L.: Secondary hormonal manipulation. In: Comprehensive Textbook of Genitourinary Oncology. Edited by N. J. Vogelzang P. T. Scardino, W. U. Shipley, D. S. Coffey and B. J. Miles. Baltimore: Williams & Wilkins, chapt. 48A, pp. 885-890, 1996.
2. Dawson, N. A.: Treatment of progressive metastatic prostate cancer. Oncology, 7: 17, 1993.
3. Scher, H. I. and Kelly, W. K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566, 1993.
4. Small, E. J. and Srinivas, S.: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 76: 1428, 1995.
5. Figg, W. D., Sartor, O., Cooper, M. R., Thibault, A., Bergan, R. C., Dawson, N., Reed, E. and Myers, C. E.: Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Amer. J. Med., 98: 412, 1995.
6. Herrada, J., Dieringer, P. and Logothetis, C. J.: Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J. Urol., 155: 620, 1996.
7. Scher, H. I., Steineck, G. and Kelly, W. K.: Hormone-refractory (D3) prostate cancer: refining the concept. Urology, 46: 142, 1995.
8. Trachtenberg, J., Halpern, N. and Pont, A.: Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J. Urol., 130: 152, 1983.
9. Trachtenberg, J. and Pont, A.: Ketoconazole therapy for advanced prostate cancer. Lancet, 2: 433, 1984.
10. Tapazoglou, E., Subramanian, M. G., Al-Sarraf, M., Kresge, C. and Decker, D. A.: High-dose ketoconazole therapy in patients with metastatic prostate cancer. Amer. J. Clin. Oncol., 9: 369, 1986.
11. Williams, G., Kerle, D. J., Ware, H., Doble, A., Dunlop, H., Smith, C., Allen, J., Yeo, T. and Bloom, S. R.: Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Brit. J. Urol., 58: 45, 1986.
12. Gerber, G. S. and Chodak, G. W.: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J. Urol., 144: 1177, 1990.
13. Trump, D. L., Havlin, K. H., Messing, E. M., Cummings, K. B., Lange, P. H. and Jordan, V. C.: High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J. Clin. Oncol., 7: 1093, 1989.
14. Muscato, J. J., Ahmann, T. A. and Johnson, K. M.: Optimal dosing of ketoconazole (keto) and hydrocortisone (HC) leads to long responses in hormone refractory prostate cancer. Proc. Amer. Soc. Clin. Oncol., 13: 229, 1994.
15. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A. and Mulder, E.: Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity heat-shock protein interaction, and transcription activation. Biochem., 31: 2393, 1992.
16. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N. and Balk, S. P.: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl. J. Med., 332: 1393, 1995.
17. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A., Tompkins, A., Steinberg, S., Figg, W. D., Linehan, W. M. and Myers, C. E.: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J. Natl. Cancer Inst., 86: 222, 1994.
18. Kelly, W. K., Scher, H. I., Mazumdar, M., Vladmis, V., Schwartz, M. and Fossa, S. D.: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 11: 607, 1993.
19. Scher, H. I., Curley, T., Geller, N., Engstrom, C., Dershaw, D. D., Lin, S. Y., Fitzpatrick, K., Nisselbaum, J., Schwartz, M. and Bezirdjian, L.: Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J. Clin. Oncol., 8: 1830, 1990.
20. Sridhara, R., Eisenberger, M. A., Sinibaldi, V. J., Reyno, L. M. and Egorin, M. J.: Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J. Clin. Oncol., 13: 2944, 1995.